摘要:
Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A2A receptor agonist—to a human undergoing myocardial imaging in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.
摘要:
Methods of treating heart failure, or decreasing blood pressure, comprising administering an NP at an appropriate dose, or in an amount sufficient to provide particular concentrations of NP, are provided.
摘要:
Medical systems and methods for treating kidney disease alone, heart failure alone, kidney disease with concomitant heart failure, or cardiorenal syndrome are described. The systems and methods are based on delivery of a chimeric natriuretic peptide to a patient. Methods for increasing peptide levels include direct peptide delivery via either an external or implantable programmable pump.
摘要:
The present application discloses methods and compositions for increasing patient tolerability during myocardial imaging comprising the administration of doses of caffeine and one or more adenosine A2A receptor agonists to a mammal undergoing myocardial imaging.
摘要:
The present application discloses methods and compositions for increasing patient tolerability during myocardial imaging comprising the administration of doses of caffeine and one or more adenosine A2A receptor agonists to a mammal undergoing myocardial imaging.
摘要:
Methods of treating heart failure, or decreasing blood pressure, comprising administering an NP at an appropriate dose, or in an amount sufficient to provide particular concentrations of NP, are provided.